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Continuing Medical Education has featured strongly in 
this journal in the past. The format has consisted either 
of “picture quizzes” or articles followed by self- 
assessment multiple choice questions. The feedback has 
been encouraging and has reflected the amount of 
preparation that has taken place for these CME articles. 
For many of the pieces we will, therefore, be con- 
tinuing the current format. But, never one to rest on 
ics laurels, the Journal will be breaking new ground. 
This is the result of asking the simple question “How 
do we best learn?” For controversial issues it is often by 
hearing two expert protagonists engaging in debate. 
We are translating this approach to the written format 
by introducing you to two imaginary professors. This 
will form the basis of the occasional article, the first of 
which follows in this issue. 
Therefore you can look forward to variety of styles 
for CME in this journal, and you can expect us to take 
the lead in developing new approaches. Regardless of 
format, the aim will be to have approximately 8 CME 
articles each year. We encourage discussion and con- 
tributions on CME from the Society members and the 
readership at large. 
The Professors’ Debate - How to manage primary 
HIV infection 
Moderator: Barry S. Peters 
Academic Department of Sexually Transmitted Diseases, United Medical Schools of Guy’s and 
St Thomas’ Hospitals, London, UK 
The two professors always begin their debate as a result 
of an iniprornptu meeting at the corner of the common 
room. A seemingly chance remark by one causes the 
other to disagree, and within a short time there is a 
heated debate. Although starting as a private discussion, 
quite frequently an audience gathers. It  is not unknown 
for both professors to play to the audience. Professor 
I. C. Cool is a calm, benign sort of chap, who has gone 
through his long medical career as a non-inter- 
ventionist, preferring to observe rather than rush in. 
Professor B. L. 0. Fire likes to investigate thoroughly, 
and to treat quickly and agressively. It has never been 
known for the two professors to agree over major 
issues. People are surprised that they spend so much 
time together: it could be that they enjoy their 
arguments. The one thing they do have in common is 
that they “know” their interpretation is the right one. 
We ask the reader to make allowances for their 
stubbornness - they are professors after all . . . 
Professor Cool: Hello, Boris, we have a case on the ward 
that will interest you. It is a young man who presented 
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with nieriingisin and a faint red rash. He  recently came 
back from trekking in Chiang-Mai in North Thailand. 
By the time we performed the lumbar puncture he was 
quite drowsy. Any ideas! 
Professor Ftre: My first thought would be meningo- 
coccal septicaemia, but then you would hardly be 
presenting that as an unusual case. What did the lumbar 
puncture show? 
Provqfessor Cool: Completely normal, including culture 
ProJssor Fir(.: Could be a wide range of things. I would 
consider encephalitis due to a range of causes. Herpes 
especially, but also other viruses. I would also like to 
know more detail about his travel history. In view of 
the rash I would like to investigate for Lyme disease, 
but the diitPrential diagnosis is still very wide. 
Profrssor Cool: So, what tests would you do Boris? 
Projessor Fire: Is this a viva? Well, I would do an MKI 
scan which might indicate pathology such as herpes 
simplex encephalitis, cerebral abscess, etc. I would 
perform herpes simplex PCR on the CSF, an ELISA 
for Borrelia hurgdoferi antibodies for Lyme disease, and 
as he has travelled to Chiang Mai I would perform thick 
and thin blood films for malaria. I would also consider 
dengue, and perform serology, using plaque reduction 
iieutralisation for IgM as this is one of the most specific 
tests. 
Profissor Cool: The MRI scan was broken at the time. 
We did none of the blood tests you suggest. Instead we 
asked a couple of simple questions, performed one test, 
and had the answer. 
Prufissor Five: So, you asked about the sexual history . . . 
Profssor Cool: Very good. We explored risk factors 
for HIV infection. He is heterosexual, but he had 
unprotected sexual intercourse with a prostitute in 
Thailand 4 weeks ago. The diagnosis is therefore one 
of primary HIV infection, or “HIV seroconversion 
illness”. 
Profimr Fire: Interesting. The conimonest presentation 
of priniary HIV infection is of course with a glandular 
fever like illness. About 50% of episodes of HIV sero- 
conversion have some symptoms or signs, as shown by 
the studies of Sinocco and Keet. When there is the 
common constellation of features it is often termed 
“acute retroviral syndrome”. I have here a copy of the 
overhead that I show my students of the features that 
commonly occur during primary HIV infection (see 
Table 1). I am not surprised the diagnosis is often 
missed, because it is conmionly confused with influenza 
or other common conditions. There was an excellent 
study in the Annals of Internal Medicine by Schacker 
et a1 who showed that even STD physicians and 
cpecialists in HIV frequently misdiagnosis primary HIV 
infection. 
Even you agree it is important to diagnose and treat 
priniary HIV infection, I presume? 
Professor Cool: No, Boris. There is no convincing argu- 
ment for treating HIV infection at this stage of the 
disease. 1 agree that diagnosis is important, but for 
different reasons. The individual can reduce the risk of 
transmitting HIV to others. Primary infection is a 
period of high infectivity as there are particularly high 
titres of circulating virus as shown by several workers 
including Clark et a1 and Daar et al. Therefore, it is 
especially important to diagnose primary infection 
because of the increased risk of horizontal or vertical 
transniission during this period. 
Also he can be monitored so that when his CD4 
count falls, or his quantitative HIV viral load rises, he 
can be offered treatment before symptoms occur. I am 
not against treatment - the newer combinations of 
antiretroviral drugs are very promising - but there is a 
time and 3 place for treatment. 
Also Boris, your overhead might do wvell to include 
the less common manifestations of priniary HIV in- 
fection - this is the overhead that I show my students 
(Table 2). 
Table 1 Professor Fire‘s overhead 
Coninion clinical features of p r m q  HIV infection 
~ ~~ 
“Clu,idiilnr~fever” like s i p i s  nrzd ,i~iiiprcims 
Pvreiia 
Lymphadenopathy 
Sorc throat 
M y  a 1 g 13 
Erythematous macuiopapuinr r s h  
Hepatosplrrioiiiegaly 
Gasrmi~ite,tinnl.~ariir~~, 
Nausea and vomiting 
Diarrhoea 
Weight 10s 
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Table 2 Professor Cool’s overhead 
Uncommon clinical features of primary HIV infection 
Severe encephalitis, occasionally with coma 
Peripheral nervous system involvement 
e.g., peripheral neuropathy or radiculopathy, Guillain-Barre 
syndrome, facial palsy, brachial neuritis 
Psychosis 
AIDS-defining opportunistic infections 
e.g., eosophageal candidiasis, PCP 
Professor Fire: Ivan, the arguments for treating primary 
HIV infection are very convincing. 
You have yourself mentioned the very high serum 
viral loads that occur during primary infection with 
HIV. The HIV viral load after primary infection is a 
powerful predictor of subsequent disease progression, as 
Mellors and his group have shown. We might be able 
to alter this set point by keeping viral replication low 
at a time when it is usually very high. Also, if we 
suppress viral replication at this time, we might be 
able to reduce the degree of viral diversity and the 
subsequent emergence of drug-resistant virus. 
Lafeuillade has shown that in some patients treated 
for primary HIV infection, there was a decline in the 
HIV antibody response; this waning of the antibody 
response when treatment is initiated early might 
indlcate a reduction in the immune damage caused by 
HIV infection. Furthermore, the treatment of primary 
HIV infection is also likely to reduce the severity of 
acute symptoms. These can be severe and Schacker’s 
study demonstrated that about 15% of cases of primary 
infection require hospitalisation. 
Prc$essor Cool Boris, you failed to consider the potential 
disadvantages of treating primary HIV infection? 
Firstly, if the individual is to be on antiretroviral drugs 
at such an early stage then there is a greater likelihood 
of the development of long-term adverse effects, or 
intolerance. Also, if drug resistance does occur at this 
stage, then the therapeutic options will have been 
narrowed at a relatively early period of the disease. This 
is more likely if the treatment is inadequate to secure 
maximal suppression of viral replication. It is also 
theoretically possible that a near complete suppression 
of the viral load at this stage might reduce the 
development of the protective host immune protective 
response to HIV. In effect, the immune system will not 
have “seen enough of the HIV antigen to mount a 
response”. And another thing, Boris - Sinnico and his 
co-workers have good evidence that the viral load in 
acute and very early HIV infection does not correlate 
with disease progression’ and therefore there may not 
be such an advantage in reducing viral load at this stage. 
Viral load will anyway naturally fall in most patients 
after primary infection. 
So, Boris, as there is no clear evidence as to who 
should be treated with primary HIV infection, would 
you just rush in and treat anyone for whom there is a 
suspicion. 
Professor Fire: No, not at  all. Although some physicians 
would treat everyone with evidence of recent primary 
infection, it is important to elicit the patient’s views and 
to estimate their likely compliance with the suggested 
regimens. It is important to provide regular support for 
those individuals where compliance is in doubt, or 
even to exclude those where it appears unlikely that 
they would adhere to a given regimen. I agree that the 
development of drug resistance at  such an early stage 
of the disease would seriously reduce their future 
options. 
Also, people should not be treated just on the 
clinical suspicion that they have primary HIV infection. 
It must be established whether they are infected with 
HIV, using techniques such as PCR for HIV RNA if 
HIV antibody tests are negative. 
I would always suggest treatment for those people 
with a severe antiretroviral syndrome. Therapy with 
antiretrovirals in these situations will probably lead to a 
quicker resolution of symptoms. Furthermore these 
individuals usually have a higher viral load and a more 
rapid progression of their HIV disease, and therefore 
might benefit most from intervention. 
Profeessov Cool Considering the fact that there is no 
consensus about treatment in the first place, it must be 
extremely difficult to decide on what treatment to use? 
Profeessov Fire: O n  the contrary - it is very easy. It is 
important to choose a treatment that is highly effective 
in suppressing viral replication. It is back to the same 
point - it could be especially disadvantageous to the 
patient to develop drug resistance at such an early stage 
of HIV infection. Therefore a combination of one of 
the potent proteinase inhibitors e.g.either indinavir, 
ritonavir or nelfinavir, should be used with at least 
’2 reverse transcriptase inhibitors e.g., zidovudine and 
ddI, or stavudine and lamivudine. Treatment regimens 
for HIV disease are becoming increasingly complex. 
A bit later I will give you some references, including 
useful web sites, of the USA and British protocols. 
A few such regimens have already been shown to be 
effective in producing large reductions in viral load 
in primary infection - I am referring to the studies 
conducted by Perrin, Tamalet and Hoen. 
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PuuJrsor Cool: The duration of treatment in these 
studies you have mentioned has been relatively short 
arid no clinical benefit, especially in the long-term has 
been shown. Which brings me onto the next question 
- how long would you treat someone with primary 
HIV infection for? Forever? 
Prqfissor Fire: There is a good argument for treating 
indefinitely. The rationale is that at  this stage of 
the disease maximal suppression of viral load is most 
easily achieved, and there might be the potential for 
elimination of the virus. Protagonists of this approach 
would aim to treat for at least 3 years before seeing the 
efiects of stopping therapy. Recent studies suggest it is 
much more difficult to eliminate HIV than might have 
been thought. Therefore I would treat for about a year, 
which is the average length of time most people would 
offer therapy for - then I would stop and manage the 
patient as for any other HIV infected individual. 
l b f i s s o r  Cool: Are you not worried about a rebound 
rise In viral load when the antiretroviral drugs are 
stopped? 
Profissoy Fire: Not unduly. Recent studies in monkeys 
suggest that the rebound in viral load that occurs when 
treatnient is stopped is much less and much more 
delayed amongst animals at an early stage of disease. 
Rebound appears to be a problem mainly of later stage 
HIV infection. 
Anyway, I have a clinic to go to now, Ivan 
Pvofssor Cool: Until next time, then, Boris . . 
That was quite some argument. Listening to them, 
I wonder what your approach would be. From the 
above argun~ents it is clear that the the most important 
aspect of primary infection is to improve our awareness 
so that we make the diagnosis in the first place. This 
\ d l  enable the individual to consider treatment options 
at the time, and also in the future. Public health will 
also be improved by a reduction in transmission. There 
are strong grounds for considering treatment for those 
with primary infection but biological plausibility must 
take second place to patient acceptability. Otherwise we 
run the risk of introducing unproved treatments on 
theoretical grounds, and restricting the future manage- 
nient options for the individual. The way to improve 
patient acceptability, and hence adherence to treatment, 
can only be by individual discussion and support. This 
cannot be eniphasised enough - without adherence to 
the regimens given, treatment is not only ineffective, it 
could be highly detrimental. We will be devoting one 
of our future CME articles to the important issues 
surrounding compliance/adherence to anti-infective 
drugs. 
If there is anything you wish to comniunicate 
to Professor I. C. Cool or Professor B. L. 0. Fire, they 
may be contacted via the CMI, by writing to Judith 
Crane at the Editorial Ofice (address on inside back 
cover of this journal). 
Pmfissor Cool: How would you follow up these patients? 
SELF-ASSESSMENT QUESTIONS 
Prqfissor Fire: Quantitative HIV viral load, along with 
0 4  measurements, are required to monitor the 
effectiveness of therapy. As there is usually a fall in viral 
load in the weeks following primary infection, there 
is little value in checking this measurement until 
approximately 3 months after treatment has been given. 
Treatment should aim for maximal suppression of viral 
load, ideally to below the limits of detection by sensitive 
assays (<20 copiedml). In order to improve the chances 
of achieving this, it is essential to follow up patients 
regularly to support them in maintaining compliance 
with the regimen. 
Pr+sor Cool: This approach seems far to aggressive for 
me. Wait for the evidence, I say. 
Pri&sor Five: 1 am also waiting for the evidence. In 
the meantime, until we have results from large clinical 
studies, we can only approach this question using 
biological plausibility. And that, to me, means we 
chould treat! 
With regards to primary HIV infection, the following 
are either true or false. 
1. The majority ofpeople with primary HIV infection 
have a “glandular fever” like illness. 
2. In some patients coma might be the only clinical 
feature suggestive of HIV seroconversion. 
3. It is important to consider an HIV antibody test if 
suspecting primary HIV infection, because getting 
a negative result will enable you to exclude HIV 
infection. 
4. You may be able to exclude primary HIV disease by 
diagnosing late stage diseases such a5 Pneitrnocystiz 
carirzii pneumonia, or oesophageal candida in some- 
one who IS HIV positive. 
5. Your treatment regimen for primary HIV disease 
might depend on knowledge about whom the 
person became infected by. 
6. If a person is found to be HIV antibody positive and 
has a nornial CD4 count and a low or undetectable 
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HIV viral load, then he is likely to have recently 
seroconverted, and you should consider treatment. 
7. If a person has a low CD4 count and a high viral 
load, then he has had HIV disease for a considerable 
time. 
8. The most crucial aspect of the management of 
someone on antiretroviral drugs for primary HIV 
infection is ensuring that they are compliant with 
their medication. 
ANSWERS 
1. 
2. 
3. 
4. 
5 .  
6 .  
7 .  
False. Approximately 50% of cases of primary HIV 
infection are asymptomatic. When symptoms do 
occur, then they are most commonly mimick 
glandular fever. 
Tme. Although encephalitis severe enough to cause 
coma is rare with primary HIV infection, it does 
occur. There may be no other accompanying signs 
and symptoms. Therefore this condition must form 
part of the differential diagnosis of the unconcious 
patient. 
False. Although it is indeed important to consider 
an HIV antibody test, a negative result does not 
exclude HIV seroconversion. At this stage of the 
disease it would be necessary to look for HIV DNA. 
False. AIDS defining conditions, such as those 
mentioned can rarely occur when there is profound 
immunosuppression associated with primary HIV 
infection. This expalins why some patients appear 
to do so well many years after an apparent AIDS 
diagnosis. 
True. If the person who transmitted HIV was on  
antiretroviral drugs, then it would be worth con- 
sidering a different combination of drugs for the 
patient. It is possible that the strain of HIV 
transmitted has already developed resistance to the 
drugs used. 
False. Approximately 10% of individuals with HIV 
infection are either slow progressors or even non- 
progressors. In order to establish a diagnosis of 
primary HIV infection, serological evidence is 
required, which means a negative HIV antibody test 
followed by demonstartion of HIV infection. In the 
absence of this, a suggestive diagnosis of primary 
HIV infection is taken to be someone with a typical 
history of retroviral syndrome who is HIV antibody 
positive. 
False. As discussed above, there can be a profound 
temporary fall in CD4 count, with an accom- 
panying very high HIV viral load, during primary 
HIV infection. 
treatment are due to poor compliance with the 
drugs, rather than the ineffectiveness of the drugs 
per se. 
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